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Endothelin-1 and Blood Pressure After Inhibition of Nitric
Oxide Synthesis in Human Septic Shock
Jurgen A.M. Avontuur, MD; Frans Boomsma, PhD; Anton H. van den Meiracker, MD;
Frank H. de Jong, PhD; Hajo A. Bruining, MD, PhD
Background—The systemic hypotension during human sepsis has been ascribed to increased production of nitric oxide
(NO). Therefore, inhibitors of NO synthesis have been used in the treatment of hypotension in patients with septic shock.
In addition, NO production may inhibit the synthesis and vasoconstrictor effects of endothelin-1 (ET-1). In this study,
we tested whether ET-1 contributed to the vasopressor action of the NO synthase inhibitor NG-nitro-L-arginine methyl
ester (L-NAME) in patients with severe septic shock.
Methods and Results—Compared with healthy volunteers, patients with septic shock had increased plasma levels of
nitrite/nitrate (3765 [SEM] versus 1265 mmol/L, P,0.01), the stable end products of NO metabolism, and ET-1
(4567 versus 362 pg/mL, P,0.001). Plasma ET-1 concentration was not related to plasma nitrite/nitrate concentration
or blood pressure. Continuous infusion of L-NAME (1 mg z kg21 z h21 IV) for 12 hours increased mean arterial pressure
by 4365% and systemic vascular resistance by 64610% (both P,0.01). The increase in blood pressure and systemic
vascular resistance correlated positively with the level of ET-1 (both P,0.005) but not with plasma nitrite/nitrate level.
L-NAME infusion did not result in significant changes in the plasma concentrations of ET-1 or nitrite/nitrate.
Conclusions—NO and ET-1 may both play a role in the cardiovascular derangements of human sepsis. Although L-NAME
does not increase ET-1 concentration in patients with septic shock, the vasopressor response induced by L-NAME
depends on the plasma level of ET-1. These findings may indicate that inhibitors of NO synthesis unmask a tonic pressor
response of ET-1 in human septic shock. (Circulation. 1999;99:271-275.)
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Recent evidence suggests a complex interaction of endo-thelium-derived factors, including endothelin-1 (ET-1)
and nitric oxide (NO), in the control of vascular smooth
muscle tone in health and disease.1 ET-1 is a 21-amino-acid
peptide with potent vasoconstrictor actions in animals and
humans.2,3 NO is a short-lived radical, derived from the
amino acid L-arginine by the enzyme NO synthase, with
direct vasodilatory action.4,5 In vitro experiments show that
continuous NO production inhibits the synthesis6 and vaso-
constrictor action of ET-1.7 Furthermore, endothelin receptor
antagonists fail to affect blood pressure in normal animals.8
This apparent absence of vascular effects of ET-1 has been
attributed to continuous NO production. This is further
supported by the finding that inhibition of NO synthesis in
rats can unmask a tonic pressor response of endothelin and
results in increased plasma levels of ET-1.9,10 So far, the
precise interaction of ET-1 and NO in humans remains to be
determined.11,12
Sepsis in humans is characterized by massive vasodilata-
tion with low systemic vascular resistance, high cardiac
output, and severe hypotension.13 Increased production of NO
by an inducible isotype of NO synthase has been held
responsible for the cardiovascular derangements during sep-
sis.5,14 High levels of nitrite and nitrate, the stable end
products of NO metabolism, are found in patients with severe
sepsis, and these levels may correlate with vasodilation.15
Analogues of L-arginine competitively inhibit the production
of NO from L-arginine16 and can reverse hypotension in
endotoxin- and cytokine-induced shock in animals.5,17 More
recently, these inhibitors of NO synthesis have been used to
increase blood pressure in sepsis in humans.18–20 At present,
it is unknown whether inhibition of NO synthesis modulates
endothelin release in septic shock. Because high levels of
endothelin-1 have been found in patients with septic
shock,21,22 we hypothesized that part of the vasoconstrictive
response after inhibition of NO synthesis may result from
increased production of ET-1.
The purpose of the present study was to examine whether
ET-1 plays a role in the increase in blood pressure after
inhibition of NO synthesis in patients with severe sepsis.
Plasma concentrations of ET-1 and nitrite/nitrate, as an
indirect measure of NO production, were measured during
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continuous infusion of the L-arginine analogue NG-nitro-L-




Our hospital Medical and Ethics Committee approved the study.
First-degree relatives were informed of the nature of the study and
gave informed consent. Eleven adult, critically ill patients in the
intensive care unit of our hospital were included in the study. All
patients met the criteria of sepsis as described by Bone et al.23 The
source for sepsis was peritonitis (n55), pneumonia (n52), pancre-
atitis (n52), mediastinitis (n51), or peritonitis with pneumonia
(n51). Patients were in shock (systolic blood pressure ,90 mm Hg
or a decrease .40 mm Hg from baseline unresponsive to fluid
challenge) on admission, requiring therapy with pressor agents. At
the time of the study, all patients were receiving dopamine .15 mg z
kg21 z min21 and/or norepinephrine .0.1 mg z kg21 z min21. All
patients required mechanical ventilation because of respiratory
failure. Four patients required continuous hemodialysis because of
renal failure. Only patients with cardiac index .3.0 L z min21 z m22
were included, because earlier reports have shown reductions of
cardiac output during inhibition of NO synthesis. Exclusion criteria
for the study were severe coronary artery stenosis (angina pectoris
grade III according to NYHA classification), pregnancy, and cardiac
index ,3.0 L z min21 z m22.
Study Protocol
All patients underwent continuous ECG monitoring and had indwell-
ing radial artery and pulmonary artery catheters (Criticath, Ohmeda).
Measurements of systemic arterial blood pressure, central venous
pressure, pulmonary artery pressure, and cardiac output (thermodi-
lution method) were made at baseline and at 0.5-, 1-, 3-, and 6-hour
intervals, for a total period of 24 hours. Systemic and pulmonary
vascular resistance were calculated according to standard formulas.
After baseline measurements, infusion of L-NAME 1 mg z kg21 z h21
was started and continued for 12 hours. To minimize the potential of
developing toxicity from high serum levels of L-NAME, infusion
was not continued for longer periods. Maximum changes in blood
pressure and systemic vascular resistance were noted after 30
minutes of L-NAME administration,20 and hemodynamic variables
at this time were used to compare with the baseline value. Concom-
itant therapy was at the discretion of the clinician managing the
patient.
Blood Samples
For later determination of plasma ET-1, nitrite/nitrate, and cortisol,
arterial blood samples (10 mL) were obtained in heparin-coated
blood collection tubes (Vacutainer) at baseline (t50), during
L-NAME infusion (t50.5, 1, 3, 6, and 12 hours), and 3, 6, and 12
hours after L-NAME infusion had stopped (t515, 18, and 24 hours).
Control values were established in 10 healthy volunteers. Blood
samples were immediately centrifuged (1500g, 10 minutes, 4°C),
and plasma was collected and stored at 280°C until tested. Creati-
nine concentration was determined by a standard method.
Determination of ET-1
ET-1 was determined, after Sep-Pak extraction, with a commercially
available radioimmunoassay kit (Nichols Institute) as previously
described.24 Normal values in our laboratory were 1 to 5 pg/mL. The
limit of detection was 1 pg/mL.
Determination of Nitrite/Nitrate Concentration
Total nitrite plus nitrate concentration was assayed as described by
Phizackerley and Al-Dabbagh.25 To reduce nitrate to nitrite, super-
natant or standards were incubated at room temperature in the
presence of Klebsiella pneumoniae under anaerobic conditions. Total
nitrite in the supernatant was subjected to the Griess reaction and
assayed spectrophotometrically. Data are reported as the sum of
nitrite plus nitrate. Normal values in our laboratory were 5 to
15 mmol/L. The limit of detection was 0.1 mmol/L.
Determination of Cortisol
Cortisol concentrations were determined with a commercially avail-
able radioimmunoassay kit (DPC) as described previously.26 Normal
values were 400 to 800 nmol/L (15 to 30 mg/dL). The limit of
detection was 28 nmol/L.
Drugs
L-NAME was obtained from Sigma Chemical Co. The hospital
pharmacy prepared a sterile and pyrogen-free solution of L-NAME
10 mg/mL, ready for intravenous infusion.
Data Analysis
All results are expressed as mean6SEM. Changes over time were
compared with baseline values by repeated-measures ANOVA.
Differences between groups were compared by Student’s t test.
Pearson correlation and scatterplots were used for analysis of
correlation between variables. A value of P,0.05 was considered
statistically significant.
Results
Patient characteristics are shown in the Table. All patients
had hypotension, low systemic vascular resistance, high
cardiac output, and increased serum creatinine due to septic
shock (Table). Compared with healthy volunteers, plasma
levels of ET-1, nitrate/nitrate, and cortisol were significantly
increased (all P,0.05, Table). Mortality at 28 days was 55%.
No correlation was found between plasma ET-1 concen-
tration and plasma nitrite/nitrate concentration (r50.07,
P.0.80), blood pressure (r520.34, P50.30), systemic vas-
cular resistance (r520.41, P50.22), or creatinine concentra-
tion (r520.13, P50.69). ET-1 concentration was 4665
pg/mL in survivors and 43612 pg/mL in nonsurvivors
(P.0.05). Plasma nitrite/nitrate concentration was negatively
correlated with systemic vascular resistance (r520.78,
P50.012) (Figure 1) but not with creatinine concentration
(r520.03, P50.93).
Continuous infusion of L-NAME 1 mg z kg21 z h21 IV
resulted in a maximum increase of mean arterial pressure by
4365% and systemic vascular resistance by 64610% (Figure
2). There was a concomitant reduction in cardiac output by
Patient Characteristics, Plasma Endothelin, Nitrite/Nitrate, and
Cortisol Concentration in Severe Septic Shock
Septic Patients Control
Age, y 51.763.9
Sex, M/F, n 10/1
MAP, mm Hg 6563 [70–110]
SVR, dyne z s z cm25 z m22 9626121 [1900–2400]
CO, L z min21 z m22 4.860.4 [2.5–3.6]
Creatinine, mmol/L 283656 [60–110]
ET-1, pg/mL 4567* 362
NOx, mmol/L 3765† 1265
Cortisol, nmol/L 753687‡ 521662
Mortality at day 28 6/11
MAP indicates mean arterial pressure; SVR, systemic vascular resistance;
CO, cardiac output; and NOx, nitrite plus nitrate. Values are displayed as
mean6SEM. Values in brackets are normal ranges.
*P,0.001, †P,0.01, and ‡P,0.05 vs healthy volunteers.
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2064%. The increase in blood pressure (r50.84, P50.001)
and systemic vascular resistance (r50.81, P50.002) during
L-NAME infusion correlated positively with the baseline
plasma concentration of ET-1 (Figure 3). The increase in
blood pressure with L-NAME did not correlate with plasma
nitrite/nitrate level (r50.12, P50.89). L-NAME infusion for
a period of 12 hours did not result in changes in the plasma
concentration levels of ET-1 (from 4567 pg/mL at baseline
to 4366 pg/mL after 12 hours of L-NAME, P.0.05) and/or
cortisol (from 753686 nmol/L at baseline to 682673 nmol/L
after 12 hours of L-NAME, P.0.05; Figure 4). Plasma
nitrite/nitrate did not change during L-NAME (from
3765 mmol/L at baseline to 3665 mmol/L after 12 hours of
L-NAME, P.0.05).
Discussion
Inhibitors of NO synthase have recently been presented as
new therapeutic tools in the management of hypotension in
septic shock in humans.18–20 The present study demonstrates
that the increases in blood pressure and the magnitude of the
vasopressor response induced by the NO synthase inhibitor
L-NAME are related to the plasma level of ET-1. These
findings may suggest that inhibitors of NO synthesis unmask
a tonic pressor response of ET-1 in human septic shock. In
addition, this study shows that prolonged inhibition of NO
synthesis with L-NAME does not further increase the already
elevated plasma ET-1 concentration.
In the present study, elevated plasma levels of ET-1 were
found in patients with severe sepsis, as has been reported by
others.21,22 The mechanism involved in the increase of ET-1
concentration during sepsis is largely unknown. High ET-1
levels could have resulted from increased synthesis and/or
diminished clearance of ET-1. Levels of circulating cyto-
kines, such as tumor necrosis factor and interleukins, are
increased in septic shock and may stimulate ET-1 production
in endothelial cells and macrophages.27,28 Furthermore, intra-
vascular leakage of ET-1 from damaged endothelial cells may
have occurred.13 Because most patients with septic shock had
impaired renal function, diminished renal clearance could
have played a role.29,30 However, no correlation was found
between plasma ET-1 and creatinine in the present study.
Figure 2. Effect of continuous infusion of L-NAME 1 mg z kg21 z
h21 IV on hemodynamic variables in patients with severe septic
shock. MAP indicates mean arterial pressure; SVR, systemic
vascular resistance; PAP, mean pulmonary artery pressure;
PVR, pulmonary vascular resistance; CO, cardiac output; and
HR, heart rate. Values are maximum changes vs baseline and
are displayed as mean6SEM. *P,0.05.
Figure 3. Relation between plasma ET-1 concentration and
increase in blood pressure (top) and systemic vascular resis-
tance (bottom) during continuous infusion of L-NAME 1 mg z
kg21 z h21 IV in patients with severe septic shock.
Figure 4. Effect of continuous infusion of L-NAME 1 mg z kg21 z
h21 IV on plasma concentrations of ET-1 (top) and cortisol (bot-
tom) in patients with severe septic shock. Time of L-NAME infu-
sion is from t50 to t512 hours. No significant changes over
time vs baseline. Values are mean6SEM.
Figure 1. Relation between plasma nitrite/nitrate (NOx) concen-
tration and systemic vascular resistance (SVR) in patients with
severe septic shock.
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This supports the idea that increased generation of endothelin
occurs in sepsis in humans, although other vascular beds,
including liver and skeletal muscles, may also contribute to
the clearance of ET-1.
The finding that high ET-1 levels coincided with high
nitrite/nitrate levels as an indirect measure of increased NO
production is not in line with previous data that indicate an
inhibitory action of NO on ET-1 release.1,6 This suggests that
the normal interaction between NO and ET-1 is disturbed
during sepsis. Abnormalities in the balance between vasocon-
stricting and vasodilating factors have been reported during
sepsis.13,31 At present, however, the exact interaction of ET-1
and NO in septic shock remains to be determined. We
hypothesize that the high circulating ET-1 concentration
helps to maintain vascular tone during sepsis and opposes the
vascular smooth muscle relaxation induced by increased NO
production. Indeed, the high circulating ET-1 levels in pa-
tients with septic shock, in the present study 45 pg/mL ('18
pmol/L), are sufficient to induce relevant vasoconstric-
tion.32,33 The fact that the increase in blood pressure with
L-NAME correlated with the level of ET-1 further supports
the idea of a continuous vasopressor tone by ET-1 during
sepsis in humans and that this vasopressor tone is unmasked
by an inhibitor of NO synthesis. Our findings are consistent
with previous reports in normal rats in which the increase in
blood pressure with L-NAME was reduced with the specific
endothelin receptor antagonist bosentan.9,10 In healthy hu-
mans34 and humans with chronic heart failure,35 endothelin
receptor antagonists can reduce blood pressure. To demon-
strate a direct relation between ET-1 and blood pressure,
however, the use of a receptor blocker specific for ET-1
would be necessary. In the present study, we did not test the
effects of an endothelin receptor antagonist. We hypothesize
that endothelin receptor antagonism during septic shock in
humans, in which plasma levels of ET-1 are high, would be
detrimental, because it may result in severe hypotension.
Whether endothelin receptor antagonists can prevent the
increase in blood pressure of NO synthase inhibitors in
humans remains to be determined.
In the present study, no increase was found in the plasma
levels of ET-1 during 12 hours of inhibition of NO synthesis
with L-NAME. These findings may suggest that ET-1 release
itself is not modulated by L-NAME in patients with septic
shock. In normal rats, acute inhibition of NO synthesis results
in modest increases in ET-1 levels, but these ET-1 levels were
measured only 15 and 35 minutes after L-NAME infusion.9,10
In contrast to these findings, chronic inhibition of NO
synthesis with L-NAME (3 weeks) in normal rats does not
increase ET-1 levels or gene expression.36 Only a few reports
are available on the NO-endothelin interaction in humans.
Although nitrovasodilators can reduce ET-1 production by
human endothelial cells in culture,37 infusion of nitroglycerin,
an NO-donating drug, does not change plasma ET-1 levels in
healthy subjects.11 In a recent study in healthy men, the NO
synthase inhibitor NG-monomethyl-L-arginine temporarily
(only after 20 minutes) increased ET-1 levels from 7.6 to 9.6
pmol/L.12 In the present study, however, we did not find a
temporary increase in already elevated ET-1 concentration.
One possible explanation is that the continuous high release
of ET-1 during sepsis resulted in a depletion of storage
vesicles with ET-1 (or its precursor).38 The results from the
present study and previous reports suggest that increased
production of ET-1 does not play a major role in the rise in
blood pressure during prolonged inhibition of NO synthesis.
However, some reservations must be made regarding
interpretation of plasma ET-1 levels. Plasma levels of ET-1
may not correctly reflect production rate, and the local
concentration of the peptide at the vascular smooth muscle
binding sites is probably more essential. For instance, big
endothelin, which needs conversion to endothelin by tissue
endothelin-converting enzyme to gain activity, is able to
cause vasoconstriction without notable increases in plasma
endothelin.39 Because the main ET-1 release seems to occur
abluminally, local concentrations of ET-1 are probably higher
than in the plasma.40 In the present study, therefore, increased
local production of ET-1 may have occurred with L-NAME
without detectable changes in plasma concentration. Similar
reservations must be made regarding nitrite/nitrate levels. NO
is but one of the ways that nitrite and nitrate are formed, and
L-NAME infusion did not result in reduced serum levels of
nitrite and nitrate, despite increased vasoconstriction. Possi-
bly, plasma levels of nitrite and nitrate do not directly reflect
the local amount of NO released, and active excretion of
nitrite/nitrate through the kidneys and gastrointestinal tract
may have influenced the plasma levels currently measured.41
Cortisol has a vital role in the maintenance of vascular tone
and endothelial function.42 Furthermore, cortisol potentiates
the vasoconstrictor actions of catecholamines.43 Thus, in-
creases in plasma cortisol may indirectly increase vasopressor
tone. Animal studies have shown that inhibition of NO
synthesis with L-NAME stimulates adrenal steroidogene-
sis.44,45 We hypothesized that increased cortisol production
might be an additional mechanism by which L-NAME
increases blood pressure. However, we found no evidence of
changes in cortisol levels during inhibition of NO synthesis in
patients with septic shock. We conclude that changes in
cortisol levels do not contribute to the increase in blood
pressure with L-NAME.
In conclusion, inhibitors of NO synthesis may unmask a
tonic pressor response of ET-1 in humans with septic shock.
Prolonged inhibition of NO synthesis does not influence the
plasma levels of ET-1. These results suggest that ET-1
maintains blood pressure in human sepsis and that plasma
ET-1 concentration may determine the vasopressor response
of NO synthase inhibitors in septic shock. These findings may
provide further evidence of interaction between NO and ET-1
in pathological conditions of the cardiovascular system in
which an imbalance between endothelium-derived vasodila-
tor and vasoconstrictor substances disturbs the normal regu-
lation of vascular tone.
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